A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma
NCT04268498
Age 18 - 75
Sex Both
Phase Phase 2
Third Opinion Trial Synopsis
This study is trying to find out if two different treatments, KRD and KRD+DARA, are better at controlling multiple myeloma than a treatment called VRD. They want to know if KRD and KRD+DARA are safer and work better.
This study is trying to find out if two different treatments, KRD and KRD+DARA, are better at controlling multiple myeloma than a treatment called VRD. They want to know if KRD and KRD+DARA are safer and work better.
Third Opinion AI Generated Synopsis
Trial Summary
This study is being done to find out whether carfilzomib, lenalidomide, and dexamethasone (KRD) or KRD and Daratumumab (KRD+DARA) might be safer and more effective ways of controlling multiple myeloma than the stand or care treatment, which is lenalidomide, bortezomib, and dexamethasone (VRD).
This study is being done to find out whether carfilzomib, lenalidomide, and dexamethasone (KRD) or KRD and Daratumumab (KRD+DARA) might be safer and more effective ways of controlling multiple myeloma than the stand or care treatment, which is lenalidomide, bortezomib, and dexamethasone (VRD).
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
